Skip to content

A clinical study of the safety and effectiveness of ionized atelocollagen based adhesion barrier(Collabarrier®) for adhesion prevention in hysteroscopic surgery

The Prospective, multicenter, double-blinded(Subject-independent evaluator), randomized, and pivotal clinical trial to compare the efficacy and safety of Collabarrier® with Guardix-SOL for the prevention of postoperative adhesion in Intrauterine surgery.

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CRIS
Registry ID
KCT0002946
Enrollment
188
Registered
2018-06-22
Start date
2017-11-23
Completion date
Unknown
Last updated
2021-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device : This study is proceeded with patients who are scheduled to have intrauterine surgery because of their gynecological diseases. Patients who completed the consent form and screening eva

Sponsors

Dalim Tissen
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Female at least 19 years old 2. Patients scheduled for intrauterine surgery because of the following gynecological diseases - Submucosal myoma - Endometrial polyp - Uterine septa - Endometrial hyperplasia - Intrauterine adhesion - Abnormal uterine bleeding 3. Patients who are willing to voluntarily participate in the trial and are willing to follow the protocol

Exclusion criteria

Exclusion criteria: If any of the following criteria are met, a target subject can not be enrolled. ? Pregnant, lactating women, and women having a pregnancy plan during the clinical trial ? Patients who intend to use an intrauterine device for contraception during the clinical trial ? Patients who need hormone therapy after intrauterine surgery ? Patients who had GnRH hormone therapy within 3 months before screening ? Patients who have local or systemic infection, endometrial cancer (uterus and endometrium, cervical cancer) and excessive uterine bleeding ? Patients who have abnormal liver function, abnormal kidney function, abnormal hemostatic function ? Patients who are applied anti-coagulants or who took systemic steroids within 1 week before surgical operation ? Patients with immunosuppression or autoimmune diseases ? Patients with uncontrolled diabetes ? Patients with hypersensitivity to the medical device for clinical trials ? Patients who have participated in other clinical trials within 30 days prior to participating in this clinical trial ? In the case that investigators made a decision that a person is inappropriate to participate in the clinical trial

Design outcomes

Primary

MeasureTime frame
the adhesion incidence rate;All adverse events that occurred to the subjects

Secondary

MeasureTime frame
the mean score of adhesion type;the mean score of adhesion extent

Countries

Korea, Republic of

Contacts

Public ContactSunghoon Kim

Yonsei University Health System, Severance Hospital

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026